ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2025
Direct oral anticoagulants in very elderly and high-bleeding-risk patients with atrial fibrillation often excluded from oral anticoagulation therapy: a nationwide population-based cohort study.
Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Edoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Trial
- Direct oral anticoagulants in elderly patients with atrial fibrillation: a decade-long nationwide retrospective cohort study.BMJ open · 2026Article
- Left atrial appendage closure in patients with atrial fibrillation: grey zones involving trials, meta-analysis, and decision-making.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Emerging strategies in venous thromboembolism: a narrative review of pharmacological innovations.Thrombosis journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimsIn the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) trial, very low-dose edoxaban (15 mg once daily) showed better efficacy and positive net clinical benefit compared with placebo in very elderly, high-bleeding-risk patients with atrial fibrillation (AF). However, there are limited data to generalize these results into daily practice. We aimed to investigate the optimal oral anticoagulant (OAC) strategy for the best net clinical benefit in ELDERCARE-AF-like patients. METHODS AND
resultsWe used the Korean nationwide claims database to identify AF patients aged ≥80 years from 2014 to 2017 who had one or more ELDERCARE-AF trial inclusion criteria. The risks of ischaemic stroke, major bleeding, all-cause death, and net clinical outcome were evaluated. Primarily, we compared patients without OAC therapy (non-OAC group) to patients with direct OAC (DOAC) therapy (DOAC group), using a propensity score weighting method. A total of 23 858 patients were included (no OAC: 16 575; warfarin: 2390; DOAC: 4893). Among the DOAC group, 69% used low dose, and 9% used very low dose. Compared with the non-OAC group, the DOAC group showed lower risks of ischaemic stroke (hazard ratio, 95% confidence interval: 0.81, 0.68-0.96) and all-cause death (0.91, 0.86-0.96) and a higher risk of major bleeding (1.44, 1.21-1.70). The DOAC group was associated with a lower risk of net clinical outcome compared with the non-OAC group (0.93, 0.88-0.98).
conclusionIn very elderly, high-bleeding-risk patients with AF, DOACs that were prescribed in usual clinical practice showed better effectiveness and positive net clinical benefit compared with no OAC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.